Disposition of 37258 shares by John Bailey of G1 Therapeutics at 4.7888 subject to Rule 16b-3
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
Slightly above 56% of G1 Therapeutics' investor base is looking to short. The analysis of current outlook of investing in G1 Therapeutics suggests that many traders are alarmed regarding G1 Therapeutics' prospects. G1 Therapeutics' investing sentiment can be driven by a variety of factors including economic data, G1 Therapeutics' earnings reports, geopolitical events, and overall market trends.
GTHX |
Filed transaction by G1 Therapeutics Director, Officer: President And Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
G1 Therapeutics Fundamental Analysis
We analyze G1 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
G1 Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
G1 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with G1 Therapeutics stock to make a market-neutral strategy. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics with similar companies.
Peers
G1 Therapeutics Related Equities
| FATE | Fate Therapeutics | 18.28 | ||||
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| SANA | Sana Biotechnology | 9.02 | ||||
| MGNX | MacroGenics | 7.06 | ||||
| HRTX | Heron Therapeuti | 5.45 | ||||
| PBYI | Puma Biotechnology | 4.95 | ||||
| PDSB | PDS Biotechnology | 1.86 | ||||
| HOOK | Hookipa Pharma | 1.61 | ||||
| DAWN | Day One | 1.53 | ||||
| MREO | Mereo BioPharma | 1.40 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| ANNX | Annexon | 0.94 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| CRBU | Caribou Biosciences | 0.45 | ||||
| ATRA | Atara Biotherapeutics | 0.65 | ||||
| ALLO | Allogene Therapeutics | 0.80 | ||||
| AXSM | Axsome Therapeutics | 1.44 | ||||
| SGMO | Sangamo Therapeutics | 1.74 | ||||
| RCUS | Arcus Biosciences | 2.28 | ||||
| CHRS | Coherus BioSciences | 3.17 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 | ||||
| LRMR | Larimar Therapeutics | 4.67 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |